Celldex Therapeutics Inc

4 de nov. de 2026, 21:07 UTC

Rhythm Pharmaceuticals surged on a $10 billion acquisition offer from AstraZeneca, boosting the State Street SPDR S&P Biotech ETF, which is also advancing.

3 de nov. de 2026, 20:56 UTC

Celldex Therapeutics, Inc. is advancing during Tuesday's session, gaining ground since Monday's close despite earlier peaks and a subsequent pullback.

2 de nov. de 2026, 21:09 UTC

Celldex Therapeutics shares fell, reflecting a broader downturn in the biotechnology sector as the SPDR S&P Biotech ETF also declined amid disappointing earnings from key holdings.

30 de out. de 2026, 19:26 UTC

The SPDR S&P Biotech ETF fell, influenced by significant declines in Iovance Biotherapeutics and Agios Pharmaceuticals due to negative analyst actions and regulatory delays.

29 de out. de 2026, 21:21 UTC

Celldex Therapeutics, Inc. shares rose in after-market trading, reaching a cumulative return of 2.04% since Thursday's close, remaining above its 20-day moving average.

28 de out. de 2026, 20:07 UTC

Celldex Therapeutics, Inc. shares are declining, following broader market trends amid macroeconomic factors like the Federal Reserve's interest rate decision and inflation concerns.

26 de out. de 2026, 20:07 UTC

Celldex Therapeutics Inc shares are moving higher as the Dallas Fed Manufacturing Index rose to 13.4, signaling expansion in manufacturing activity.

22 de out. de 2026, 19:56 UTC

Shares of Celldex Therapeutics Inc are declining amid negative market reaction to Moderna's cancer vaccine trial results, impacting the SPDR S&P Biotech ETF (XBI).

21 de out. de 2026, 19:46 UTC

Celldex Therapeutics Inc shares are declining, having pulled back from earlier gains amid broader market weakness and trading significantly below its 20-day moving average.

20 de out. de 2026, 20:31 UTC

Celldex Therapeutics Inc shares are trading lower in after-market hours, shifting from an initial gain to a notable loss since Tuesday's close.

19 de out. de 2026, 20:01 UTC

Celldex Therapeutics Inc shares are trading significantly higher, reaching a notable peak late morning before a slight retracement amid recent declines.

16 de out. de 2026, 20:01 UTC

Celldex Therapeutics Inc shares are declining amid a broader downturn in the biotechnology sector, as the SPDR S&P Biotech ETF (XBI) also falls.

15 de out. de 2026, 19:26 UTC

The SPDR S&P Biotech ETF is trading higher, supported by analyst upgrades for biotech firms, including Goldman Sachs' price target raise for Moderna.

14 de out. de 2026, 23:36 UTC

Celldex Therapeutics Inc experienced a modest decline during after-market hours on Wednesday, continuing a pattern of lower daily closes and remaining below its 20-day moving average.

13 de out. de 2026, 20:01 UTC

Celldex Therapeutics shares are declining, following a brief rebound earlier in the session, as the SPDR S&P Biotech ETF also faces losses.

9 de out. de 2026, 19:46 UTC

Shares of Celldex Therapeutics Inc are advancing, supported by a rise in the SPDR S&P Biotech ETF following gains from Moderna amid cancer vaccine partnership news.

8 de out. de 2026, 20:07 UTC

Celldex Therapeutics Inc shares are declining, reflecting broader market weakness amid significant downturns and ongoing challenges, remaining well below the 20-day moving average.

6 de out. de 2026, 20:00 UTC

Celldex Therapeutics Inc shares fell amid a broader biotechnology sector decline, influenced by Federal Reserve comments on inflation risks and a widening U.S. trade deficit.

5 de out. de 2026, 20:01 UTC

Celldex Therapeutics Inc is advancing, regaining momentum after pulling back earlier, amid unusual strength while trading near the lower end of its one-month range.

2 de out. de 2026, 20:00 UTC

Celldex Therapeutics Inc shares fell more than two percent, reversing earlier gains and remaining significantly below its 20-day moving average.

1 de out. de 2026, 19:46 UTC

Celldex Therapeutics Inc shares fell, continuing a trend from Wednesday, amid a slight downturn in the State Street SPDR S&P Biotech ETF.

30 de set. de 2026, 23:45 UTC

Celldex Therapeutics Inc is rising in after-market trading, gaining ground since Wednesday's close, despite remaining below its 20-day moving average.

29 de set. de 2026, 19:46 UTC

Celldex Therapeutics Inc shares are higher today after positive feedback on Barzolvolimab, with analysts raising the price target to $64 per share.

28 de set. de 2026, 22:35 UTC

Celldex Therapeutics Inc is trading modestly higher in after-market hours, recovering from an early dip but remains below its 20-day moving average.

25 de set. de 2026, 19:20 UTC

Celldex Therapeutics Inc shares fell sharply after an early high, currently trading below Thursday's close and notably under its 20-day moving average.

23 de set. de 2026, 20:02 UTC

Celldex Therapeutics shares fell sharply amid safety concerns from its Phase 3 CSU study, despite Overweight ratings from Morgan Stanley and Leerink Partners.

22 de set. de 2026, 23:06 UTC

Celldex Therapeutics Inc is seeing a modest increase in after-market trading, recovering from an earlier session low and gaining since Tuesday's close.

21 de set. de 2026, 20:01 UTC

Celldex Therapeutics Inc shares fell sharply, diverging from recent gains as the biotechnology sector shows varied performance.

18 de set. de 2026, 20:02 UTC

Celldex Therapeutics Inc shares fell sharply, remaining well below their 20-day moving average after a notable high earlier in the session.

17 de set. de 2026, 20:07 UTC

Celldex Therapeutics Inc is modestly higher in Thursday's session, rebounding from an earlier pullback, amid a boost from positive developments in the biotech sector.